DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Tumors often have defects in DNA damage response (DDR) pathways, creating dependencies on remaining DDR mechanisms.
• Understanding DDR pathways and tumor genomic landscapes enables novel therapeutic strategies.

Purpose of the Study:

• To review the roles of ATM, ATR, CHK1, and WEE1 proteins in DDR.
• To discuss their potential as targets for cancer therapy, including monotherapy and combination strategies.

Main Methods:

• Review of preclinical and clinical evidence for DDR inhibitors.
• Analysis of synthetic lethality approaches targeting tumors with specific DDR defects.
• Discussion of combination strategies with radiotherapy, chemotherapy, and targeted agents.

Main Results:

• Specific inhibitors targeting ATM, ATR, CHK1, and WEE1 have been developed.
• These inhibitors demonstrate potential antineoplastic activity in preclinical and clinical studies.
• Combination therapies show promise for targeting specific tumor subsets.

Conclusions:

• Targeting DDR proteins like ATM, ATR, CHK1, and WEE1 is a viable therapeutic strategy in oncology.
• Combination therapies involving these inhibitors may enhance antitumor efficacy.
• Further research is warranted to optimize treatment strategies for specific tumor types.